Physician profile
Mandy Gentry
NPI 1588188619
$1,113.17
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.80 · 2022: $387 · 2023: $390 · 2024: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.77 | 2022-2024 | Caplyta |
| Abbvie INC. | $204.74 | 2022-2024 | |
| Lundbeck LLC | $112.92 | 2022-2024 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $91.38 | 2022-2024 | Rexulti |
| Alkermes, INC. | $82.44 | 2022-2024 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $72.81 | 2022-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $61.41 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $53.30 | 2022-2024 | Spravato |
| Axsome Therapeutics, INC. | $42.44 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $34.26 | 2023-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $34.07 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $29.17 | 2024 | Hetlioz, Fanapt |
| Corium, LLC | $25.99 | 2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $18.90 | 2023 | Jornay Pm |
| Novo Nordisk INC | $15.80 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $15.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.